EUVIMEDEUVIMED entdecken
Leitlinie

National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge

Paul L Hess, Paula Langner, Paul A Heidenreich, Utibe Essien, Chelsea Leonard, Stanley A Swat, Vincenzo Polsinelli, Steven T Orlando, Gary K Grunwald, P Michael Ho

JACC: Heart Failure · 2024-06 · 12 (6) · 1059-1070

DOI: 10.1016/j.jchf.2024.02.014 ↗

Kurz gefasst

Leitlinie in der Zeitschrift JACC: Heart Failure, 2024-06. Verfasst von Paul L Hess und 9 weiteren Autor:innen. Beteiligte Einrichtung: Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA; University of Colorado Anschutz Medical Campus, Aurora, Colorado. Electronic addres…. Hauptthemen laut MEDLINE: Heart Failure, Patient Discharge, Guideline Adherence, Angiotensin Receptor Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: HSRD VA, Department of Veterans Affairs, American Heart Association Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The use of recommended heart failure (HF) medications has improved over time, but opportunities for improvement persist among women and at rural hospitals. OBJECTIVES: This study aims to characterize national trends in performance in the use of guideline-recommended pharmacologic treatment for HF at U.S. Department of Veterans Affairs (VA) hospitals, at which medication copayments are modest. METHODS: Among patients discharged from VA hospitals with HF between January 1, 2013, and December 31, 2019, receipt of all guideline-recommended HF pharmacotherapy among eligible patients was assessed, consisting of evidence-based beta-blockers; angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or angiotensin receptor neprilysin inhibitors; mineralocorticoid receptor antagonists; and oral anticoagulation. RESULTS: Of 55,560 patients at 122 hospitals, 32,304 (58.1%) received all guideline-recommended HF medications for which they were eligible. The proportion of patients receiving all recommended medications was higher in 2019 relative to 2013 (OR: 1.54; 95% CI: 1.44-1.65). The median of hospital performance was 59.1% (Q1-Q3: 53.2%-66.2%), improving with substantial variation across sites from 2013 (median 56.4%; Q1-Q3: 50.0%-62.0%) to 2019 (median 65.7%; Q1-Q3: 56.3%-73.5%). Women were less likely to receive recommended therapies than men (adjusted OR [aOR]: 0.84; 95% CI: 0.74-0.96). Compared with non-Hispanic White patients, non-Hispanic Black patients were less likely to receive recommended therapies (aOR: 0.83; 95% CI: 0.79-0.87). Urban hospital location was associated with lower likelihood of medication receipt (aOR: 0.73; 95% CI: 0.59-0.92). CONCLUSIONS: Forty-two percent of patients did not receive all recommended HF medications at discharge, particularly women, minority patients, and those receiving care at urban hospitals. Rates of use increased over time, with variation in performance across hospitals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailurePatient DischargeGuideline AdherenceAngiotensin Receptor AntagonistsAdrenergic beta-AntagonistsHumansFemaleMaleUnited StatesAgedPractice Guidelines as TopicMineralocorticoid Receptor AntagonistsMiddle AgedAngiotensin-Converting Enzyme InhibitorsHospitals, VeteransAnticoagulantsAged, 80 and over

Stichwörter der Autor:innen

heart failure hospitalizationprescribing patternsquality of care

Substanzen

Angiotensin Receptor AntagonistsAdrenergic beta-AntagonistsMineralocorticoid Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsAnticoagulants

Autor:innen und Institutionen

  • Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA; University of Colorado Anschutz Medical Campus, Aurora, Colorado. Electronic address: paul.hess@cuanschutz.edu.
  • Rocky Mountain Regional VA Medical Center, Aurora, Colorado, USA; University of Colorado Anschutz Medical Campus, Aurora, Colorado.
  • Palo Alto VA Medical Center, Palo Alto, California, USA; Stanford University School of Medicine, Palo Alto, California, USA.
  • Greater Los Angeles VA Medical Center, Los Angeles, California, USA.
  • University of Colorado Anschutz Medical Campus, Aurora, Colorado.

Förderung

  • HSRD VA
  • Department of Veterans Affairs
  • American Heart Association Inc

Zitieren

APA

Hess, P. L., Langner, P., Heidenreich, P. A., Essien, U., Leonard, C., Swat, S. A., Polsinelli, V., Orlando, S. T., Grunwald, G. K., & Ho, P. M. (2024). National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge. JACC: Heart Failure, 12(6), 1059-1070. https://doi.org/10.1016/j.jchf.2024.02.014

Vancouver

Hess PL, Langner P, Heidenreich PA, Essien U, Leonard C, Swat SA, et al. National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge. JACC: Heart Failure. 2024;12(6):1059-1070. doi:10.1016/j.jchf.2024.02.014

BibTeX
@article{Hess2024,
  author = {Hess, Paul L and Langner, Paula and Heidenreich, Paul A and Essien, Utibe and Leonard, Chelsea and Swat, Stanley A and Polsinelli, Vincenzo and Orlando, Steven T and Grunwald, Gary K and Ho, P Michael},
  title = {National Trends in Hospital Performance in Guideline-Recommended Pharmacologic Treatment for Heart Failure at Discharge},
  journal = {JACC: Heart Failure},
  year = {2024},
  volume = {12},
  number = {6},
  pages = {1059--1070},
  doi = {10.1016/j.jchf.2024.02.014}
}
Kostenlos starten →